Novartis AG Common Stock (NVS)
R&D to Revenue
19.14%
Quarterly · Period ending:
NVS R&D to Revenue
Latest reported19.14%period ending
Latest reported19.14%period ending
NVS Quarterly R&D/Revenue (0.00% → 19.14%)
Latest values, visible window
High-resolution chart · PNG
NVS r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 19.1352% | |
| 21.3147% | |
| 21.2732% | |
| 20.5042% | |
| 18.381% | |
| 17.3715% | |
| 20.9618% | |
| 18.1597% | |
| 18.3888% | |
| 19.9752% | |
| 21.7986% | |
| 32.4595% | |
| 19.6169% | |
| 23.3095% | |
| 18.6597% | |
| 23.5741% | |
| 19.0906% | |
| 18.1052% | |
| 17.8154% | |
| 17.805% | |
| 18.0533% | |
| 18.5206% | |
| 17.9048% | |
| 17.116% | |
| 21.0033% | |
| 16.2103% | |
| 22.4363% | |
| 17.6174% | |
| 17.0576% | |
| 20.0698% | |
| 17.5571% | |
| 18.8565% | |
| 18.2442% | |
| 17.7551% | |
| 19.0064% | |
| 17.641% | |
| 16.5039% | |
| 18.4048% | |
| 20.4982% | |
| 18.0212% | |
| 17.2727% | |
| 17.282% | |
| 19.3065% | |
| 17.541% | |
| 17.1061% | |
| 16.9398% | |
| 18.9981% | |
| 16.2481% | |
| 15.614% | |
| 16.9596% | |
| 17.5552% | |
| 17.1703% | |
| 16.9202% | |
| 16.1692% | |
| 17.3945% | |
| 15.6065% | |
| 15.7142% | |
| 16.0641% | |
| 16.8245% | |
| 16.4627% | |
| 15.85% | |
| 15.3846% | |
| 17.9204% | |
| 19.8752% | |
| 15.8795% | |
| 16.4859% | |
| 16.3408% | |
| 16.1647% | |
| 16.7753% | |
| 17.0663% | |
| 17.7232% | |
| 17.6065% | |
| 16.0783% | |
| 16.3861% | |
| 18.1595% | |
| 15.8077% | |
| 16.266% | |
| 16.023% | |
| 16.5039% | |
| 15.5585% | |
| 14.7273% | |
| 13.8773% | |
| 16.8171% | |
| 14.0299% | |
| 13.9263% | |
| 14.8072% | |
| 16.284% | |
| 15.0489% | |
| 13.8248% | |
| 14.2642% | |
| 16.2259% | |
| 14.1385% | |
| 15.2023% | |
| 14.7352% | |
| 14.0167% | |
| 13.3623% | |
| 12.7724% | |
| 0% | |
| 0% | |
| 0% |